Breaking Down China Risun Group Limited Financial Health: Key Insights for Investors

If you're tracking cyclical industrial plays, China Risun Group Limited's recent figures demand a close look: 2024 revenue reached RMB47.54 billion (up 3.2% year-on-year) but revenue for the six months to June 30, 2025 plunged to RMB20.55 billion (down 18.5% YoY) even as coke and refined chemicals output rose by 25.3% and 11.5% respectively; profitability paints a starker picture with profit attributable to owners collapsing to RMB20.1 million (a 97.7% drop) and EPS falling to 0.5 cents, margins compressed (H1 2025 net margin 0.4%, EBITDA margin 9.0%) while leverage and liquidity raise red flags-total borrowings climbed 15.65% to RMB35.13 billion, debt-to-equity sits at 2.25, interest coverage is about 1.01, current ratio only 0.62 and quick ratio 0.16, cash and short-term investments slid 27.86% to RMB2.76 billion, free cash flow is negative RMB220.96 million, yet valuation metrics show a mix of signals (EV/EBITDA 12.74, EV/Sales 1.04, P/B 0.83, forward P/E 41.27) against a market cap of HK$9.71 billion and share price HK$2.27 as of Dec 19, 2025-read on to unpack the risks, liquidity stress, and growth opportunities from coke capacity expansion to hydrogen and digitalization that investors must weigh

China Risun Group Limited (1907.HK) Revenue Analysis

• 2024 revenue: RMB47.54 billion (+3.2% vs 2023)
• H1 2025 revenue: RMB20.55 billion (-18.5% YoY)
• Revenue per employee (latest reported): ~RMB6.53 million
• Primary drivers of 2025 revenue decline: lower product prices and softer demand in select markets
• Operational offsets in H1 2025: coke production +25.3%, refined chemicals production +11.5%

China Risun Group Limited (1907.HK) Profitability Metrics

Key profitability indicators for China Risun Group Limited (1907.HK) show a sharp contraction in 2024 followed by marginal recovery in operating profitability for the first half of 2025, while return and net margin remained under pressure.

• 2024 profit attributable to owners: RMB 20.1 million (down 97.7% YoY).
• Basic earnings per share (EPS) 2024: RMB 0.5 cents (down 97.4% YoY).
• Six months ended 30 June 2025: net profit margin 0.4% (previous year 0.5%).
• Six months ended 30 June 2025: EBITDA margin 9.0% (slight improvement YoY).
• Six months ended 30 June 2025: ROE 0.5% (previous year 0.6%).
• Primary drivers: higher operational costs and lower product prices, weighing on bottom-line metrics.

• Investors should note the divergence between operating profitability (EBITDA margin improvement to 9.0%) and bottom-line metrics (net margin and ROE decline), indicating cost and pricing pressures still compressing net returns.
• Comparative micro-metrics (EPS and profit attributable) signal pronounced earnings volatility in FY2024 that has not yet been fully resolved by mid-2025.

Further context and investor-focused details can be found here: Exploring China Risun Group Limited Investor Profile: Who's Buying and Why?

China Risun Group Limited (1907.HK) - Debt vs. Equity Structure

• Total borrowings: RMB 35.13 billion (up 15.65% year-over-year).
• Total liabilities: RMB 47.62 billion (up 4.99% year-over-year).
• Total equity: RMB 15.64 billion.
• Debt-to-equity ratio: 2.25x - a high leverage level relative to equity base.
• Interest coverage ratio: 1.01x - near-breakeven ability to cover interest from operating income.
• Return on equity (ROE): 0.34% - very low return for equity holders.

• Refinancing risk: Rising borrowings (+15.65%) increase dependence on capital markets and bank facilities; any tightening in credit conditions could raise funding costs or limit rollovers.
• Liquidity pressure: Interest coverage near 1.0x implies operating income barely covers interest - limited headroom for earnings shocks or cyclical downturns.
• Leverage sensitivity: At 2.25x debt-to-equity, modest asset or earnings declines can materially impair equity value and trigger covenant tests.
• Equity return erosion: ROE of 0.34% signals minimal return to shareholders despite high leverage, suggesting inefficient capital deployment or near-term profit weakness.

• Stress-test scenarios: Model EBITDA declines (e.g., -10% to -30%) to assess interest coverage under stress and time-to-default probability given current maturities.
• Maturity and covenant map: Prioritize review of debt maturities and covenant triggers - large near-term amortizations would materially increase refinancing needs.
• Cash flow focus: Track operating cash flow conversion and free cash flow after interest to gauge actual deleveraging capacity.
• Capital raise options: Given weak ROE and high leverage, equity issuance would dilute existing holders but could materially improve solvency; debt restructuring or asset disposals are alternative levers.

China Risun Group Limited (1907.HK) - Liquidity and Solvency

Key liquidity and solvency indicators for the six months ending June 30, 2025 point to tightening short-term financial flexibility and increased funding pressure.

• Current ratio: 0.62 - potential difficulty meeting short-term obligations.
• Quick ratio: 0.16 - very limited ability to cover immediate liabilities without liquidating inventory.
• Cash and short-term investments: RMB2.76 billion, down 27.86% year-on-year.
• Net change in cash (6 months ended Jun 30, 2025): RMB118.68 million - a 90.10% decrease YoY.
• Free cash flow: negative RMB220.96 million - operating and investing cash outflows exceeded inflows.
• Primary drivers in 2025: higher capital expenditures and reduced operating cash flow.

• Implications for creditors and short-term creditors: elevated refinancing and rollover risk given low coverage ratios.
• Implications for equity holders: negative free cash flow and shrinking cash buffers could pressure dividends and capex funding choices.
• Potential management levers: slow or reprioritize capex, improve working capital management (AR/Inventory/DPO), or raise external financing.

For broader context on shareholder composition and investor interest, see: Exploring China Risun Group Limited Investor Profile: Who's Buying and Why?

China Risun Group Limited (1907.HK) - Valuation Analysis

• Enterprise value (EV) / EBITDA: 12.74 - a moderate multiple suggesting earnings are valued reasonably versus peers in commodity/property-linked sectors.
• EV / Sales: 1.04 - the enterprise value is roughly in line with annual revenue, indicating market pricing close to top-line performance.
• Price / Book (P/B): 0.83 - the stock trades below its book value, signaling potential undervaluation or balance-sheet concerns.
• Forward P/E: 41.27 - high forward multiple, reflecting strong market expectations for future earnings expansion.
• Market capitalization: HK$9.71 billion; Share price: HK$2.27 (as of 19 Dec 2025).

• Investment tension: P/B < 1 suggests possible value opportunity, while forward P/E of 41.27 indicates the market is pricing significant future earnings growth - investors should reconcile balance-sheet valuation with earnings expectations.
• Relative positioning: an EV/EBITDA of 12.74 places China Risun between value and growth profiles; compare directly with industry peers for context.
• Practical next steps for analysis:
  • Review most recent sales and EBITDA to convert EV multiples into implied EV and to assess sustainability of margins.
  • Examine net debt and asset quality to validate the P/B signal.
  • Stress-test forward earnings assumptions underlying the 41.27 forward P/E.

China Risun Group Limited (1907.HK) Risk Factors

• High financial leverage: debt-to-equity ratio of 2.25, indicating elevated financial risk and sensitivity to interest-cost increases.
• Poor short-term liquidity: current ratio of 0.62, suggesting potential difficulty meeting near-term obligations without asset disposals or new financing.
• Operational volatility: exposure to fluctuating raw material prices (coal, feedstock) and evolving environmental and industry regulations that can compress margins.
• Profitability pressure in 2025: reported decline in revenue and profitability during 2025, which can erode investor confidence and negatively affect stock performance.
• Strategic partnership disruption: termination of the framework agreement with Beijing SinoHytec in September 2025 may reduce collaboration opportunities and pipeline projects.
• Asset and capability impact: disposal of a subsidiary in October 2025 could alter operational capabilities, production footprint and market position depending on the disposed assets.

• Investor considerations:
  • Scenario analysis should include sensitivity to rising interest rates given leverage (stress-test interest coverage).
  • Assess working capital needs and contingent funding plans given a current ratio < 1.0.
  • Monitor commodity price trends and regulatory announcements that materially affect margins.

China Risun Group Limited (1907.HK) - Growth Opportunities

• Target: reach 30 million tonnes of coke production capacity by 2025, aiming to capture ~10% of the estimated ~300 million tonnes domestic+global market capacity.
• International expansion: entering Southeast Asian and Central Asian markets to diversify revenue away from domestic cyclical demand.
• Intelligent manufacturing & digitalization: automation, predictive maintenance and process optimization to reduce unit costs and improve yields.
• Hydrogen energy value chain: leveraging by-product gases and feedstock to develop hydrogen/refining offerings, creating higher-margin, lower-carbon revenue streams.
• Strategic partnerships & M&A: targeted deals to secure raw materials, downstream integration and proprietary technologies for cleaner production.
• Customized production & branding: move up the value chain via specialty coke grades, branded products and long-term supply agreements to increase customer stickiness.

• Operational upside from intelligent manufacturing: expected 5-10% reduction in unit operating costs from automation and process control improvements.
• Hydrogen opportunity: capturing by-product hydrogen and monetizing it could add incremental revenue streams; pilot-to-scale ramp may represent multi-year development with high ROI if supported by policy incentives.
• Revenue diversification: even a 10-20% revenue contribution from overseas sales and specialty products would materially reduce cyclical exposure to domestic steel demand.
• Acquisition leverage: targeted bolt-on M&A could accelerate capacity/tech gains and provide immediate market share uplift versus organic-only expansion.